Incyte says psoriasis drug meets main goal
Incyte Corp said its psoriasis drug met the main and secondary goals in a mid-stage trial, sending its shares up about 6 percent.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral agent for the treatment of moderate to severe psoriasis that demonstrates improved efficacy and lasting remission when compared with Amgen/Wyeth/Takeda's Enbrel would earn a higher patient share in the United States than in Europe, according to surveyed US and European dermatologists.